Nektar Wins $90M Jury Verdict Against Eli Lilly Over Rezpeg Partnership Breach

Event Analysis

On September 24, 2026, a California federal jury found that Eli Lilly and Company breached the implied covenant of good faith and fair dealing in its co-development agreement with Nektar Therapeutics over rezpegaldesleukin (Rezpeg), an autoimmune-disease drug. As reported by Law360, the jury awarded Nektar $90 million in damages, with interest to be determined separately by the court — meaning the final liability figure could exceed $90 million.

The result is asymmetric in its significance. For Lilly, a pharmaceutical giant, $90 million is a manageable legal charge relative to its overall financial scale. For Nektar — a clinical-stage biotechnology company — the verdict is more material, though it lands well below the approximately $1 billion Nektar had argued it was owed. The gap between the claimed and awarded amounts signals that the jury accepted Lilly's liability but rejected Nektar's maximum damages case. Post-trial motions and a potential Lilly appeal introduce further uncertainty about the ultimate recovery amount and timing.

The strategic significance extends beyond the dollar figure. This verdict is a concrete example of how regulatory final rulings and court decisions act as market catalysts in the pharmaceutical sector. The case puts a spotlight on the legal risks embedded in drug co-development partnerships — particularly when a larger partner deprioritizes or walks away from a joint program. Investors in biotech companies relying on big-pharma collaboration agreements will now weigh that abandonment risk more carefully, as explored in our drug pipeline catalysts guide.

What This Means for Traders

The most direct market signal is modestly bullish for Nektar and a minor headwind for Lilly. Nektar's reported ~5% equity gain reflects investor relief at a liability confirmation, even if the $90 million award is significantly below the $1 billion sought. The stock move is consistent with a binary event resolving positively — but the upside may be capped by appeal risk and the long timeline to actual cash collection. Traders should treat Nektar's position as a contingent asset story: positive on verdict, but not a clean cash catalyst until appeals are exhausted.

For Lilly, the direct financial impact is unlikely to drive material repricing given the company's scale, but the verdict adds a discrete litigation liability and may prompt analysts to revisit assumptions around partnering-program exits. The pharma M&A and licensing landscape could see incremental risk-premium expansion for deals where large pharma holds the termination option. Sector-wide, the event reinforces caution around smaller biotechs heavily dependent on a single large-partner relationship — a theme relevant across the energy, pharma, and tech M&A space.

Volatility for Nektar is likely to remain elevated in the near term as the market digests appeal probability and court-determined interest. Lilly's volatility impact appears minimal at current scale.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices and commodities from one crypto-funded account. Leverage up to 2000x on selected products, subject to eligibility; fees are tiered by 30-day volume.